Keywords: FDA, Roche GlaxoSmithKline, oristat

US FDA reviewing Roche weight loss drug Xenical and OTC alli from GlaxoSmithKline

Article | 25 August 2009

Print This

The US Food and Drug Administration says that it is reviewing adverse event reports of liver injury in patients taking ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in